1323 CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies

Natasha Girgis; Yu Christie; Zohra Merazga; Steven Hatfield; Alex Histed; Fan Zhao; Raymond Moniz; Kristin Yeung; Fulvio Diaz; Wynona Bautista; John Ross; Saso Cemerski; Anish Suri; Matteo Levisetti; Steven Quayle

doi:10.1136/jitc-2022-SITC2022.1323

Article info

Regular and Young Investigator Award Abstracts

Novel Single-Agent Immunotherapies

1323 CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies

Free

Authors

Natasha Girgis Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Yu Christie Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Zohra Merazga Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Steven Hatfield Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Alex Histed Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Fan Zhao Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Raymond Moniz Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Kristin Yeung Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Fulvio Diaz Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Wynona Bautista Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
John Ross Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Saso Cemerski Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Anish Suri Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Matteo Levisetti Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles
Steven Quayle Cue Biopharma, Boston, MA, USA PubMed articles Google scholar articles

Citation

Girgis N, Christie Y, Merazga Z, et al

1323 CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies

Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1323

Publication history

First published November 7, 2022.

Online issue publication

April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password